Skip to main
EVAX

EVAX Stock Forecast & Price Target

EVAX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Evaxion AS has demonstrated significant advancements in its clinical-stage oncology pipeline with an impressive 81% prediction accuracy of immunogenic neoantigens as reported in the revised PIONEER AI model data, indicating consistent improvement in predictive capabilities. The company achieved a promising overall response rate (ORR) of 75% for its EVX-01 therapy in combination with pembrolizumab, surpassing previous efficacy metrics and comparing favorably to competitor data. Additionally, the high percentage of patients experiencing deepened responses and sustained effectiveness at the 24-month mark highlights the robustness of Evaxion's innovative approach to personalized vaccines, reinforcing its leadership position in the neoantigen cancer vaccine sector.

Bears say

Evaxion AS faced negative market reactions to its stock, despite a strong data update regarding its product EVX-01, primarily due to the lack of clear expectations regarding the product's contribution to overall commercial viability. The company's reliance on AI-driven immunotherapy models appears to be met with skepticism from investors, reflected in the stock's underperformance. Furthermore, the contrasting sentiment highlights an ongoing struggle to translate clinical advancements into tangible financial growth, contributing to a cautious outlook on the company's future.

EVAX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evaxion Biotech A/S and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evaxion Biotech A/S (EVAX) Forecast

Analysts have given EVAX a Strong Buy based on their latest research and market trends.

According to 3 analysts, EVAX has a Strong Buy consensus rating as of Jan 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evaxion Biotech A/S (EVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.